share_log
Breakings ·  Jun 17 20:44
Evaxion Biotech A/S: One-Year Clinical Efficacy Readout From Phase 2 Study Is on Track for Q3 2024
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment